We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
(-24%)
Cap. Flow
-$166M
Cap. Flow
% of AUM
-6.88%
Top 10 Holdings %
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$54.6M |
| 2 |
APLT
Applied Therapeutics
APLT
|
+$33.4M |
| 3 |
Centene
CNC
|
+$31.6M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$22.8M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$19.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$106M |
| 2 |
UnitedHealth
UNH
|
+$80.1M |
| 3 |
Johnson & Johnson
JNJ
|
+$64.2M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$35.2M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.03% |
| 2 | Consumer Staples | 1.05% |
| 3 | Consumer Discretionary | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Bristol-Myers Squibb
BMY
$130B
| – | – |
-150,000
| Closed | -$9.63M |
|
127
Corvus Pharmaceuticals
CRVS
$1.21B
| – | – |
-150,000
| Closed | -$816K |
|
128
Insmed
INSM
$28.9B
| – | – |
-800,000
| Closed | -$19.1M |
|
129
Pfizer
PFE
$152B
| – | – |
-10,962
| Closed | -$407K |
|
|
ICPT
130
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-54,400
| Closed | -$6.74M |
|
|
SRGA
131
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| – | – |
-65,000
| Closed | -$5.34M |
|
|
RARX
132
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-750,000
| Closed | -$35.2M |
|
|
DERM
133
DELISTED
Dermira, Inc.
DERM
| – | – |
-650,000
| Closed | -$9.85M |
|
|
ACHN
134
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-3,685,000
| Closed | -$22.2M |
|
|
WCG
135
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-320,500
| Closed | -$106M |
|
|
BOLD
136
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-410,000
| Closed | -$24.5M |
|
|
MDCO
137
DELISTED
Medicines Co
MDCO
| – | – |
-307,699
| Closed | -$26.1M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.
- Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
- Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
- Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
- Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
- Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
- Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
- Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.
Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.